Alnylam Pharmaceuticals | ALNY - Interest Expense On Debt

Alnylam Pharmaceuticals reported $29.91M in Interest Expense on Debt for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Interest Expense On Debt Change
Alnylam Pharmaceuticals ALNY:US USD 29.91M 11.17M
Amgen AMGN:US USD 415M 47M
Avrobio Inc AVRO:US USD 482K 149K
Biocryst Pharmaceuticals BCRX:US USD 26.46M 1.68M
Biomarin Pharmaceutical BMRN:US USD 3.63M 1.05M
Intercept Pharmaceuticals ICPT:US USD 2.81M 2.43M
IONIS PHARMACEUT IONS:US USD 1.73M 408K
Moderna Inc MRNA:US USD 10M 2M
Neurocrine Biosciences NBIX:US USD 1.1M 100K
Novartis NVS:US USD 219M 4M
Ptc Therapeutics PTCT:US USD 25.9M 6.42M
Regeneron Pharmaceuticals REGN:US USD 17.4M 2.1M
Regulus Therapeutics RGLS:US USD 175K 13K
Sarepta Therapeutics SRPT:US USD 6.69M 8.05M
Vertex Pharmaceuticals VRTX:US USD 11.6M 2.1M
YTE INCY:US USD 667K 26K